Recovering scientist turned early stage VC A biotech optimist fighting gravity

A Decade of Discovery
May 9, 2019

This blog was written by Jeb Keiper, CEO of Nimbus Therapeutics LLC, as part of the From The Trenches feature of LifeSciVC. It is with great excitement that we at Nimbus are ringing in our 10th birthday this month. It’s

Leave a comment

An Encyclopedia Of Advice For Startup Boards
May 6, 2019

Startups management teams often have a love-hate relationship with their Board of Directors: while Boards can be hugely helpful and constructive in the best of times, they can be dysfunctional and damaging in the worst. And most CEOs enjoy complaining

Leave a comment

Maybe It’s Innate
April 30, 2019

This blog was written by Samantha Truex, Atlas EIR and CEO of Quench Bio, as part of the From The Trenches feature of LifeSciVC. Recently I read the article What’s Wrong With Me? that I saw re-posted on Twitter.  It’s

Leave a comment

Why Reputation Is More Important Than Ever For Biotech Companies … And What You Can Do About It
April 24, 2019

This blog was co-written by Deanna Petersen, Chief Business Officer of AVROBIO, and Paul Newman, head of Corporate Communications, as part of the From The Trenches feature of LifeSciVC. “It takes twenty years to build a reputation, and five minutes

Leave a comment

Sheer Heart Attack: What Happens When Your Partner Gets Acquired in The Middle of Negotiations
April 11, 2019

This blog was written by Tariq Kassum, COO of Obsidian Therapeutics, as part of the From The Trenches feature of LifeSciVC. Every morning before I go to work, I review my calendar for the day. This gets me into the

Leave a comment

Cats And The Future Of Machine Learning In Drug Discovery
April 9, 2019

This blog was written by Jonathan Montagu, CEO and founder of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC. The predictions around the impact of artificial intelligence (AI) have been broad reaching but it’s clear that

Leave a comment

Sharing An Innate Desire To Address Inflammation: Novartis and IFM Team Up
April 1, 2019

Today Novartis announced the acquisition of IFM Therapeutics’ portfolio of NLRP3 antagonists, via the purchase of IFM Tre, a subsidiary of IFM (here, here). These immunomodulatory medicines target the inflammasome, a key innate immune node whose pathologic chronic activation is associated with

Leave a comment

Arteaus’ Final Chapter: Monetization Of The Emgality Royalties
April 1, 2019

Back in September 2018, the FDA approved Lilly’s Emgality, an anti-CGRP antibody therapy, for the preventative treatment of episodic and chronic migraine. Arteaus Therapeutics, a biotech company founded by Atlas Venture in 2011, played a critical role in Emgality’s early

Leave a comment

If You Build It, Will They Come? Addressing The Value Equation
March 12, 2019

This blog was written by Ankit Mahadevia, CEO and founder of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC. Over my experience building several therapeutics companies, I’ve sometimes observed a Field of Dreams approach to therapeutics:

Leave a comment

Sharing The Adaptive Ski Experience With The Biotech Community
February 25, 2019

JB Harvey broke his personal record earlier this winter by skiing over 22 trails in a single day at Loon Mountain. It was an awesome day. And 22 runs would be a huge day for anyone, but it was particularly

Leave a comment

Keep Calm and Carry On: How to Survive an FDA Inspection
February 21, 2019

This blog was written by Aoife Brennan, CEO of Synlogic, as part of the From The Trenches feature of LifeSciVC. It was apparently random, although I secretly suspect it was karmic punishment for my lack of imagination in writing the

Leave a comment

Leave A Ladder Down
February 19, 2019

This post was written by Ros Deegan, President and CBO of Bicycle Therapeutics, as part of the From The Trenches feature of LifeSciVC.   In May 2007, I trekked to Everest Base Camp in Nepal. Situated at an altitude of over

Leave a comment